This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Myriad Genetics Announces Participation In Innovative Collaboration To Accelerate Hereditary Cancer Research

Stocks in this article: MYGN

SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) and leading cancer experts from the Memorial Sloan Kettering Cancer Center (MSKCC), Mayo Clinic, Abramson Cancer Center of the University of Pennsylvania and other laboratories are teaming up in a new partnership that will dramatically advance the understanding of the risks associated with multiple cancer genes that are being analyzed through next generation sequencing technology. Specifically, the partners will collaborate on the creation of a research study called the Prospective Registry of Multiplex Testing (PROMPT).

The goals of the study are three-fold: 1) to create an online registry of individuals consenting to a prospective follow up after having been tested with a pan-cancer panel test such as Myriad's myRisk™ Hereditary Cancer; 2) to provide infrastructure for the curation of specific genetic variants detected; and 3) to facilitate additional studies to characterize the significance of the genetic mutations. Myriad will contribute thousands of genetic mutations and its scientific expertise gained from having tested over 1.3 million patients for hereditary cancer risk.

"We look forward to collaborating with leading cancer centers to help end preventable hereditary cancers. Myriad's contribution of thousands of genetic mutations to the PROMPT study will help make this goal a reality by ensuring that researchers have access to critical, potentially life-saving information," said Richard Wenstrup, M.D. chief medical officer at Myriad.  "Through this innovative data sharing partnership with some of the country's best cancer genetics centers, we can more efficiently study genetic mutations, maximize the impact of our research investments and help ensure that patients will receive the best care possible."

This announcement continues Myriad's long-standing commitment to research collaborations. Myriad currently is engaged in scientific collaborations with more than 50 academic research institutions to help advance medical and scientific knowledge and healthcare overall.  For more information visit: www.myriad.com/responsibility/research-collaborations/ .

About the Prospective Registry of Multiplex Testing (PROMPT)

The PROMPT registry is a database that will include patients identified with deleterious or suspected deleterious mutations in any of the cancer susceptibility genes targeted in this research study. Individuals will be offered the opportunity to join the registry by participating in a process of informed consent.  The study's Principal Investigators are Mark Robson, M.D., of the Clinical Genetics Service at MSKCC; Susan Domchek, M.D., of the Abramson Cancer Center of the University of Pennsylvania; Fergus Couch, Ph.D., of the Division of Experimental Pathology, Mayo Clinic and Kenneth Offit, M.D., MPH, chief of the Clinical Genetics Service at MSKCC.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs